Yasufumi Sawada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasufumi Sawada has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Hisakazu Ohtani
Faculty of Pharmacy, Keio University, 1-5-30, Shibakoen Minato-ku, Tokyo, 105-8512, Japan; Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan; School of Medicine, Keio University, Tokyo, Japan; Department of Pharmacy, Keio University Hospital, Tokyo, Japan
5 shared publications Hideyasu Murakami
Department of Medico‐Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, 3‐1‐1 Maidashi, Higashi‐ku, Fukuoka 812‐8582, Japan
3 shared publicationsNoriko Koyabu
11Department of Medico-Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
3 shared publicationsHirotami Matsuo
Department of Medico-Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University , 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582
2 shared publicationsMichihiko Kuwano
44Research Center for Innovative Cancer Therapy, 21st Century COE Program for Medical Sciences, Kurume University, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan
2 shared publicationsTakeshi Uchiumi
33Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
2 shared publications
Latest Publications
- Open Access
- 1 December 2004
- Published by Wiley in British Journal of Pharmacology
- Vol. 143 (7) , 856-864
Effects of grapefruit juice and orange juice components on P‐glycoprotein‐ and MRP2‐mediated drug efflux
We investigated the effects of grapefruit juice (GFJ) and orange juice (OJ) on drug transport by MDR1 P‐glycoprotein (P‐gp) and multidrug resistance protein 2 (MRP2), which are efflux transporters expressed in human small intestine. We examined the transcellular transport and uptake of [3H]vinblastine (VBL) and [14C]saquinavir in a human colon carcinoma cell line (Caco‐2) and in porcine kidney epithelial cell lines transfected with human MDR1 cDNA and human MRP2 cDNA, LLC‐GA5‐COL150, and LLC‐MRP2, respectively. In Caco‐2 cells, the basal‐to‐apical transports of [3H]VBL and [14C]saquinavir were greater than those in the opposite direction. The ratio of basal‐to‐apical transport to apical‐to‐basal transport of [3H]VBL and [14C]saquinavir by Caco‐2 cells was reduced in the presence of MK571 (MRPs inhibitor), verapamil (P‐gp inhibitor), cyclosporin A (inhibitor of both), 50% ethyl acetate extracts of GFJ and OJ, or their components (6′,7′‐dihydroxybergamottin, bergamottin, tangeretin, hepatomethoxyflavone, and nobiletin). Studies of transport and uptake of [3H]VBL and [14C]saquinavir with MDR1 and MRP2 transfectants showed that VBL and saquinavir are transported by both P‐gp and MRP2. GFJ and OJ components inhibited the transport by MRP2 as well as P‐gp. However, their inhibitory potencies for P‐gp or MRP2 were substrate‐dependent. The present study has revealed that GFJ and OJ interact with not only P‐gp but also MRP2, both of which are expressed at apical membranes and limit the apical‐to‐basal transport of VBL and saquinavir in Caco‐2 cells. British Journal of Pharmacology (2004) 143, 856–864. doi:10.1038/sj.bjp.0706008
- 1 December 2004
- Published by Wiley in British Journal of Pharmacology
- Vol. 143 (7) , 856-864
Open AccessEffects of grapefruit juice and orange juice components on P‐glycoprotein‐ and MRP2‐mediated drug efflux
We investigated the effects of grapefruit juice (GFJ) and orange juice (OJ) on drug transport by MDR1 P‐glycoprotein (P‐gp) and multidrug resistance protein 2 (MRP2), which are efflux transporters expressed in human small intestine. We examined the transcellular transport and uptake of [3H]vinblastine (VBL) and [14C]saquinavir in a human colon carcinoma cell line (Caco‐2) and in porcine kidney epithelial cell lines transfected with human MDR1 cDNA and human MRP2 cDNA, LLC‐GA5‐COL150, and LLC‐MRP2, respectively. In Caco‐2 cells, the basal‐to‐apical transports of [3H]VBL and [14C]saquinavir were greater than those in the opposite direction. The ratio of basal‐to‐apical transport to apical‐to‐basal transport of [3H]VBL and [14C]saquinavir by Caco‐2 cells was reduced in the presence of MK571 (MRPs inhibitor), verapamil (P‐gp inhibitor), cyclosporin A (inhibitor of both), 50% ethyl acetate extracts of GFJ and OJ, or their components (6′,7′‐dihydroxybergamottin, bergamottin, tangeretin, hepatomethoxyflavone, and nobiletin). Studies of transport and uptake of [3H]VBL and [14C]saquinavir with MDR1 and MRP2 transfectants showed that VBL and saquinavir are transported by both P‐gp and MRP2. GFJ and OJ components inhibited the transport by MRP2 as well as P‐gp. However, their inhibitory potencies for P‐gp or MRP2 were substrate‐dependent. The present study has revealed that GFJ and OJ interact with not only P‐gp but also MRP2, both of which are expressed at apical membranes and limit the apical‐to‐basal transport of VBL and saquinavir in Caco‐2 cells. British Journal of Pharmacology (2004) 143, 856–864. doi:10.1038/sj.bjp.0706008
- 19 February 2003
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 24 (3) , 105-114
Potentiation of domperidone‐induced catalepsy by a P‐glycoprotein inhibitor, cyclosporin A
The distribution of domperidone (DOM), a peripheral dopamine D2 receptor antagonist, to the brain is restricted by P‐glycoprotein (P‐gp) at the blood–brain barrier (BBB) and for this reason, DOM rarely causes parkinsonian symptoms, such as extrapyramidal side effects (EPS), unlike other dopamine D2 antagonists. In this study, we aimed to investigate whether cyclosporin A (CsA), a P‐gp inhibitor, potentiates EPS induced by DOM.The intensity of EPS was assessed in terms of the duration of catalepsy in mice. D1, D2 and mACh receptor occupancies at the striatum were measured in vivo and in vitro. Moreover, the distribution of DOM to the brain was investigated by using an in situ brain perfusion technique. The intensity of DOM‐induced catalepsy was significantly potentiated by the coadministration of CsA. The in vivo occupancies of D1, D2 and mACh receptors, as well as the brain distribution of DOM, were increased by CsA. These results suggest that CsA increases the brain distribution of DOM by inhibiting P‐gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D1 and D2 receptors. The risk of DOM‐induced parkinsonism may be enhanced by the coadministration of CsA. Copyright © 2003 John Wiley & Sons, Ltd.
- 19 February 2003
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 24 (3) , 105-114
Potentiation of domperidone‐induced catalepsy by a P‐glycoprotein inhibitor, cyclosporin A
The distribution of domperidone (DOM), a peripheral dopamine D2 receptor antagonist, to the brain is restricted by P‐glycoprotein (P‐gp) at the blood–brain barrier (BBB) and for this reason, DOM rarely causes parkinsonian symptoms, such as extrapyramidal side effects (EPS), unlike other dopamine D2 antagonists. In this study, we aimed to investigate whether cyclosporin A (CsA), a P‐gp inhibitor, potentiates EPS induced by DOM.The intensity of EPS was assessed in terms of the duration of catalepsy in mice. D1, D2 and mACh receptor occupancies at the striatum were measured in vivo and in vitro. Moreover, the distribution of DOM to the brain was investigated by using an in situ brain perfusion technique. The intensity of DOM‐induced catalepsy was significantly potentiated by the coadministration of CsA. The in vivo occupancies of D1, D2 and mACh receptors, as well as the brain distribution of DOM, were increased by CsA. These results suggest that CsA increases the brain distribution of DOM by inhibiting P‐gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D1 and D2 receptors. The risk of DOM‐induced parkinsonism may be enhanced by the coadministration of CsA. Copyright © 2003 John Wiley & Sons, Ltd.
- 1 August 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (8) , 1055-1063
Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier
In‐situ rat and mouse brain perfusion data indicated that the brain distribution of ramosetron (R‐ramosetron), a 5‐hydroxytryptamine3 (5‐HT3) receptor antagonist, was extremely low compared with that expected from its lipophilicity. We hypothesized the involvement of an efflux system(s) and investigated the contribution of P‐glycoprotein to efflux transport of ramosetron across the blood‐brain barrier by means of an in‐vitro uptake study in cell lines that over‐express P‐glycoprotein. We examined the contributions of mdr1a, mdr1b and MDR1 P‐glycoprotein by using LV500 cells, MBEC4 cells and LLC‐GA5‐COL300 cells, which over‐express mdr1a P‐glycoprotein, mdr1b P‐glycoprotein and MDR1 P‐glycoprotein, respectively. The uptake of [14C]ramosetron by LV500 cells and LLC‐GA5‐COL300 cells was significantly lower than that by the respective parental cells. Next, we studied the effects of P‐glycoprotein inhibitors, verapamil and ciclosporin, on uptake of [14C] ramosetron by these cell lines. The uptake of [14C]ramosetron by LV500 cells and LLC‐GA5‐COL300 cells was significantly increased in the presence of verapamil or ciclosporin, while verapamil did not affect the uptake of [14C]ramosetron by MBEC4 cells. These results indicate that the efflux of [14C]ramosetron is partly mediated by mdr1a P‐glycoprotein, but not by mdr1b P‐glycoprotein, and that there is a difference in substrate specificity between mdr1a P‐glycoprotein and mdr1b P‐glycoprotein. Further, [14C]ramosetron was confirmed to be effluxed by human MDR1 P‐glycoprotein. We conclude that the limited distribution of ramosetron to the brain is due, at least in part, to efflux mediated by the P‐glycoprotein at the blood‐brain barrier.
- 1 August 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (8) , 1055-1063
Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier
In‐situ rat and mouse brain perfusion data indicated that the brain distribution of ramosetron (R‐ramosetron), a 5‐hydroxytryptamine3 (5‐HT3) receptor antagonist, was extremely low compared with that expected from its lipophilicity. We hypothesized the involvement of an efflux system(s) and investigated the contribution of P‐glycoprotein to efflux transport of ramosetron across the blood‐brain barrier by means of an in‐vitro uptake study in cell lines that over‐express P‐glycoprotein. We examined the contributions of mdr1a, mdr1b and MDR1 P‐glycoprotein by using LV500 cells, MBEC4 cells and LLC‐GA5‐COL300 cells, which over‐express mdr1a P‐glycoprotein, mdr1b P‐glycoprotein and MDR1 P‐glycoprotein, respectively. The uptake of [14C]ramosetron by LV500 cells and LLC‐GA5‐COL300 cells was significantly lower than that by the respective parental cells. Next, we studied the effects of P‐glycoprotein inhibitors, verapamil and ciclosporin, on uptake of [14C] ramosetron by these cell lines. The uptake of [14C]ramosetron by LV500 cells and LLC‐GA5‐COL300 cells was significantly increased in the presence of verapamil or ciclosporin, while verapamil did not affect the uptake of [14C]ramosetron by MBEC4 cells. These results indicate that the efflux of [14C]ramosetron is partly mediated by mdr1a P‐glycoprotein, but not by mdr1b P‐glycoprotein, and that there is a difference in substrate specificity between mdr1a P‐glycoprotein and mdr1b P‐glycoprotein. Further, [14C]ramosetron was confirmed to be effluxed by human MDR1 P‐glycoprotein. We conclude that the limited distribution of ramosetron to the brain is due, at least in part, to efflux mediated by the P‐glycoprotein at the blood‐brain barrier.
- 1 May 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (5) , 729-733
Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil
Domperidone (DOM), a peripheral dopamine D2 receptor antagonist, is a substrate of P-glycoprotein (P-gp). Therefore, the transport of DOM into the brain may be restricted by P-gp function at the blood-brain barrier, and when the function of P-gp is impaired by ATP depletion under conditions of brain ischaemia (e.g. cerebral thrombosis), side-effects may be induced as a result of increased distribution of DOM into the brain. In this study, we investigated the effects of brain ischaemia and verapamil, a P-gp inhibitor, on the permeability coefficient-surface area product (PS values) of DOM across the blood-brain barrier by using an in-situ rat brain perfusion technique. The PS values of DOM were increased 3.4- and 3.6-fold after brain ischaemia for 10 and 20 min, respectively. Furthermore, co-administration of verapamil significantly increased the PS values of DOM by 42.6- and 43.3-fold in the normal and ischaemia groups, respectively. Brain vascular volume was not affected by ischaemia or verapamil. These results show that the transport of DOM into the brain is restricted by P-gp and that the brain distribution of DOM can be increased by cerebral ischaemia or co-administration of a P-gp inhibitor.
- 1 May 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (5) , 729-733
Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil
Domperidone (DOM), a peripheral dopamine D2 receptor antagonist, is a substrate of P-glycoprotein (P-gp). Therefore, the transport of DOM into the brain may be restricted by P-gp function at the blood-brain barrier, and when the function of P-gp is impaired by ATP depletion under conditions of brain ischaemia (e.g. cerebral thrombosis), side-effects may be induced as a result of increased distribution of DOM into the brain. In this study, we investigated the effects of brain ischaemia and verapamil, a P-gp inhibitor, on the permeability coefficient-surface area product (PS values) of DOM across the blood-brain barrier by using an in-situ rat brain perfusion technique. The PS values of DOM were increased 3.4- and 3.6-fold after brain ischaemia for 10 and 20 min, respectively. Furthermore, co-administration of verapamil significantly increased the PS values of DOM by 42.6- and 43.3-fold in the normal and ischaemia groups, respectively. Brain vascular volume was not affected by ischaemia or verapamil. These results show that the transport of DOM into the brain is restricted by P-gp and that the brain distribution of DOM can be increased by cerebral ischaemia or co-administration of a P-gp inhibitor.
- 1 May 2001
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 53 (5) , 643-651
In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation
To predict, quantitatively, the extent of drug interaction during repeated administration of a metabolic inhibitor, we analysed the effects of erythromycin treatment under several regimens on the area under the concentration curve (AUC) of midazolam in rats. Midazolam was administered into the portal vein 12 h after erythromycin treatment for 1, 2 or 3 days, or 12, 24, 36, 48, 72 and 96 h after erythromycin treatment for 4 days, and the plasma-concentration profiles of midazolam were analysed to assess the AUC. Moreover, the contents of total cytochrome P450 and inactive metabolic intermediate (MI) complex were simultaneously quantitated. While the AUC value of midazolam was not affected by the administration of erythromycin for 1 day, repeated administration of erythromycin evoked an increase in AUC ratio (AUC in erythromycin-treated rats/AUC in vehicle-treated rats), which reached a maximum value of 1.99 at 12 h after 4 days' treatment with erythromycin. The total content of cytochrome P450 in liver microsomes was unaffected by erythromycin treatment. Although the MI complex was undetectable after 1 day's treatment with erythromycin, its content increased with duration of erythromycin treatment, and the complex disappeared after the end of erythromycin treatment with a half-life of 12.3 h. In conclusion, the interaction between erythromycin and midazolam could be well predicted when the formation of MI complex in the liver was taken into account.
- 1 May 2001
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 53 (5) , 643-651
In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation
To predict, quantitatively, the extent of drug interaction during repeated administration of a metabolic inhibitor, we analysed the effects of erythromycin treatment under several regimens on the area under the concentration curve (AUC) of midazolam in rats. Midazolam was administered into the portal vein 12 h after erythromycin treatment for 1, 2 or 3 days, or 12, 24, 36, 48, 72 and 96 h after erythromycin treatment for 4 days, and the plasma-concentration profiles of midazolam were analysed to assess the AUC. Moreover, the contents of total cytochrome P450 and inactive metabolic intermediate (MI) complex were simultaneously quantitated. While the AUC value of midazolam was not affected by the administration of erythromycin for 1 day, repeated administration of erythromycin evoked an increase in AUC ratio (AUC in erythromycin-treated rats/AUC in vehicle-treated rats), which reached a maximum value of 1.99 at 12 h after 4 days' treatment with erythromycin. The total content of cytochrome P450 in liver microsomes was unaffected by erythromycin treatment. Although the MI complex was undetectable after 1 day's treatment with erythromycin, its content increased with duration of erythromycin treatment, and the complex disappeared after the end of erythromycin treatment with a half-life of 12.3 h. In conclusion, the interaction between erythromycin and midazolam could be well predicted when the formation of MI complex in the liver was taken into account.